You can help our author matching system! If you notice any publications incorrectly attributed to this author, please
sign in and mark matches as correct or incorrect.
|
Kumar D, Kashyap MK, Yu Z, et al. (2022) Modulation of RNA splicing associated with Wnt signaling pathway using FD-895 and pladienolide B. Aging. 14: 2081-2100 |
Rao R, Husain A, Bharti AC, et al. (2019) Discovery of a novel connecting link between Renin-Angiotensin System and cancer in Barrett's Esophagus by Proteomic screening Proteomics Clin Appl |
Tungekar A, Mandarthi S, Mandaviya PR, et al. (2018) ESCC ATLAS: A population wide compendium of biomarkers for Esophageal Squamous Cell Carcinoma. Scientific Reports. 8: 12715 |
Barbhuiya MA, Kashyap MK, Puttamallesh VN, et al. (2018) Identification of spleen tyrosine kinase as a potential therapeutic target for esophageal squamous cell carcinoma using reverse phase protein arrays. Oncotarget. 9: 18422-18434 |
Kashyap MK, Amaya-Chanaga CI, Kumar D, et al. (2017) Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. Journal of Hematology & Oncology. 10: 112 |
Leon B, Kashyap M, Chan W, et al. (2017) A Challenging Pie to Splice: Drugging the Spliceosome. Angewandte Chemie (International Ed. in English) |
Zhang X, Maity T, Kashyap MK, et al. (2017) Quantitative tyrosine phosphoproteomics of EGFR tyrosine kinase inhibitor-treated lung adenocarcinoma cells reveals potential novel biomarkers of therapeutic response. Molecular & Cellular Proteomics : McP |
León B, Kashyap MK, Chan WC, et al. (2017) Das Spliceosom als Angriffspunkt für Pharmaka Angewandte Chemie. 129: 12218-12230 |
Barile E, Marconi GD, De SK, et al. (2016) hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents. Acs Chemical Biology |
Choi MY, Kashyap MK, Kumar D. (2016) The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor. Best Practice & Research. Clinical Haematology. 29: 40-53 |